Citation: | Jiabin Wu, Ke Li, Muge Zhou, Haoyang Gao, Wenhong Wang, Weihua Xiao. Natural compounds improve diabetic nephropathy by regulating the TLR4 signaling pathway[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.01.014 |
[1] |
H. Sun, P. Saeedi, S. Karuranga, et al., IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045, Diabetes Res. Clin. Pract. 183 (2022), 109119.
|
[2] |
X. Wang, J. Zhao, Y. Li, et al., Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression, Front. Immunol. 13 (2022), 1090989.
|
[3] |
N. Samsu, Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment, Biomed Res. Int. 2021 (2021), 1497449.
|
[4] |
S. Rayego-Mateos, J.L. Morgado-Pascual, L. Opazo-Rios, et al., Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy, Int. J. Mol. Sci. 21 (2020), 3798.
|
[5] |
Y. Wang, Y. Zhang, Kidney and innate immunity, Immunol. Lett. 183 (2017) 73-78.
|
[6] |
M. Liu, K. Zen, Toll-like receptors regulate the development and progression of renal diseases, Kidney Dis. 7 (2021) 14-23.
|
[7] |
Q. Feng, D. Liu, Y. Lu, et al., The interplay of renin-angiotensin system and toll-like receptor 4 in the inflammation of diabetic nephropathy, J. Immunol. Res. 2020 (2020), 6193407.
|
[8] |
M. Lin, S.C.W. Tang, Toll-like receptors: Sensing and reacting to diabetic injury in the kidney, Nephrol. Dial. Transplant 29 (2014) 746-754.
|
[9] |
T. Rodrigues, D. Reker, P. Schneider, et al., Counting on natural products for drug design, Nat. Chem. 8 (2016) 531-541.
|
[10] |
Y.S. Kanwar, L. Sun, P. Xie, et al., A glimpse of various pathogenetic mechanisms of diabetic nephropathy, Annu. Rev. Pathol. 6 (2011) 395-423.
|
[11] |
M.K. Arora, U.K. Singh, Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update, Vascul. Pharmacol. 58 (2013) 259-271.
|
[12] |
Y.C. Lin, Y.H. Chang, S. Yang, et al., Update of pathophysiology and management of diabetic kidney disease, J. Formos. Med. Assoc. 117 (2018) 662-675.
|
[13] |
S.C.W. Tang, W.H. Yiu, Innate immunity in diabetic kidney disease, Nat. Rev. Nephrol. 16 (2020) 206-222.
|
[14] |
A. Flyvbjerg, The role of the complement system in diabetic nephropathy, Nat. Rev. Nephrol. 13 (2017) 311-318.
|
[15] |
F.B. Hickey, F. Martin, Diabetic kidney disease and immune modulation, Curr. Opin. Pharmacol. 13 (2013) 602-612.
|
[16] |
J. Chen, Q. Liu, J. He, et al., Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target, Front. Immunol. 13 (2022), 958790.
|
[17] |
W. Jun, H. Makino, Innate immunity in diabetes and diabetic nephropathy, Nat. Rev. Nephrol. 12 (2016) 13-26.
|
[18] |
K. Takeda, S. Akira, Toll-like receptors in innate immunity, Int. Immunol. 17 (2005) 1-14.
|
[19] |
T.H. Mogensen, Pathogen recognition and inflammatory signaling in innate immune defenses, Clin. Microbiol. Rev. 22 (2009) 240-273.
|
[20] |
V. Peek, E. Neumann, T. Inoue, et al., Age-dependent changes of adipokine and cytokine secretion from rat adipose tissue by endogenous and exogenous toll-like receptor agonists, Front. Immunol. 11 (2020), 1800.
|
[21] |
R. Medzhitov, P. Preston-Hurlburt, C.A. Jr Janeway, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature 388 (1997) 394-397.
|
[22] |
B.S. Park, J.O. Lee, Recognition of lipopolysaccharide pattern by TLR4 complexes, Exp. Mol. Med. 45 (2013), e66.
|
[23] |
C.G. Leon, R. Tory, J. Jia, et al., Discovery and development of toll-like receptor 4 (TLR4) antagonists: A new paradigm for treating sepsis and other diseases, pharm. Res. 25 (2008) 1751-1761.
|
[24] |
M.M. Garcia, C. Goicoechea, M. Molina-Alvarez, et al., Toll-like receptor 4: A promising crossroads in the diagnosis and treatment of several pathologies, Eur. J. Pharmacol. 874 (2020), 172975.
|
[25] |
E. Schweighoffer, J. Nys, L. Vanes, et al., TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK, J. Exp. Med. 214 (2017) 1269-1280.
|
[26] |
J.M. Reynolds, G.J. Martinez, Y. Chung, et al., Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation, Proc. Natl. Acad. Sci. USA 109 (2012) 13064-13069.
|
[27] |
H. Mudaliar, C. Pollock, J. Ma, et al., The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose, PLoS One. 9 (2014), e108844.
|
[28] |
J. Su, J. Ren, H. Chen, et al., microRNA-140-5p ameliorates the high glucose-induced apoptosis and inflammation through suppressing TLR4/NF-κB signaling pathway in human renal tubular epithelial cells, Biosci. Rep. 40 (2020), BSR20192384.
|
[29] |
M.C. Banas, B. Banas, K.L. Hudkins, et al., TLR4 links podocytes with the innate immune system to mediate glomerular injury, J. Am. Soc. Nephrol. 19 (2008) 704-713.
|
[30] |
K. Newton, V.M. Dixit, Signaling in innate immunity and inflammation, Cold Spring Harb. Perspect. Biol. 4 (2012), a006049.
|
[31] |
M. Taghavi, A. Khosravi, E. Mortaz, et al., Role of pathogen-associated molecular patterns (PAMPS) in immune responses to fungal infections, Eur. J. Pharmacol. 808 (2017) 8-13.
|
[32] |
B. Mahaling, S.W.Y. Low, M. Beck, et al., Damage-associated molecular patterns (DAMPs) in retinal disorders, Int. J. Mol. Sci. 23 (2022), 2591.
|
[33] |
A. Poltorak, P. Ricciardi-Castagnoli, S. Citterio, et al., Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation, Proc. Natl. Acad. Sci. USA 97 (2000) 2163-2167.
|
[34] |
A.J. Jenkins, V. Velarde, R.L. Klein, et al., Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells, Diabetes 49 (2000) 2160-2169.
|
[35] |
G.H. Tesch, MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy, Am. J. Physiol. Renal Physiol. 294 (2008) F697-F701.
|
[36] |
M. Yu, H. Wang, A. Ding, et al., HMGB1 signals through toll-like receptor (TLR) 4 and TLR2, Shock 26 (2006) 174-179.
|
[37] |
J. Thompson, P. Wilson, K. Brandewie, et al., Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy, Am. J. Pathol. 179 (2011) 1179-1187.
|
[38] |
K. Ohashi, V. Burkart, S. Flohe, et al., Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex, J. Immunol. 164 (2000) 558-561.
|
[39] |
A. Asea, M. Rehli, E. Kabingu, et al., Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR) 2 and TLR4, J. Biol. Chem. 277 (2002) 15028-15034.
|
[40] |
T. Kuwabara, K. Mori, M. Mukoyama, et al., Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice, Diabetologia. 55 (2012) 2256-2266.
|
[41] |
Y. Okamura, M. Watari, E.S. Jerud, et al., The extra domain A of fibronectin activates Toll-like receptor 4, J. Biol. Chem. 276 (2001) 10229-10233.
|
[42] |
A. Lewis, R. Steadman, P. Manley, et al., Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis, Histol. Histopathol. 23 (2008) 731-739.
|
[43] |
H. Yokoyama, K. Sato, M. Okudaira, et al., Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy, Kidney Int. 56 (1999) 650-658.
|
[44] |
A.F. McGettrick, L.A.J. O’Neill, Regulators of TLR4 signaling by endotoxins, Subcell. Biochem. 53 (2010) 153-171.
|
[45] |
L. Liu, J.J. Steinle, Loss of TLR4 in mouse Muller cells inhibits both MyD88-dependent and-independent signaling, PLoS One 12 (2017), e0190253.
|
[46] |
N.N. Kuzmich, K.V. Sivak, V.N. Chubarev, et al., TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis, Vaccines 5 (2017), 34.
|
[47] |
Y. Lu, W.C. Yeh, P.S. Ohashi, LPS/TLR4 signal transduction pathway, Cytokine. 42 (2008) 145-151.
|
[48] |
K. Takeda, S. Akira, TLR signaling pathways, Semin. Immunol. 16 (2004) 3-9.
|
[49] |
T. Lawrence, The nuclear factor NF-kappaB pathway in inflammation, Cold Spring Harb. Perspect. Biol. 1 (2009), a001651.
|
[50] |
A. Oeckinghaus, M.S. Hayden, S. Ghosh, Crosstalk in NF-κB signaling pathways, Nat. Immunol. 12 (2011) 695-708.
|
[51] |
R. Medzhitov, Toll-like receptors and innate immunity, Nat. Rev. Immunol. 1 (2001) 135-145.
|
[52] |
T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors, Nat. Immunol. 11 (2010) 373-384.
|
[53] |
M. Yamamoto, S. Sato, H. Hemmi, et al., Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway, Science 301 (2003) 640-643.
|
[54] |
M. Yamamoto, S. Sato, H. Hemmi, et al., TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway, Nat. Immunol. 4 (2003) 1144-1150.
|
[55] |
N. Bayan, N. Yazdanpanah, N. Rezaei, Role of toll-like receptor 4 in diabetic retinopathy, Pharmacol. Res. 175 (2022), 105960.
|
[56] |
C. Gong, Z. Li, C. Qin, et al., Hyperin protects against LPS-induced acute kidney injury by inhibiting TLR4 and NLRP3 signaling pathways, Oncotarget 7 (2016) 82602-82608.
|
[57] |
R. Feng, Y. Xiong, Y. Lei, et al., Lysine-specific demethylase 1 aggravated oxidative stress and ferroptosis induced by renal ischemia and reperfusion injury through activation of TLR4/NOX4 pathway in mice, J. Cell. Mol. Med. 26 (2022) 4254-4267.
|
[58] |
F. Yang, J. Chen, X.R. Huang, et al., Regulatory role and mechanisms of myeloid TLR4 in anti-GBM glomerulonephritis, Cell. Mol. Life Sci. 78 (2021) 6721-6734.
|
[59] |
G. Garibotto, A. Carta, D. Picciotto, et al., Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy, J. Nephrol. 30 (2017) 719-727.
|
[60] |
J. Kim, E. Sohn, C.S. Kim, et al., The role of high-mobility group box-1 protein in the development of diabetic nephropathy, Am. J. Nephrol. 33 (2011) 524-529.
|
[61] |
H. Kaur, A. Chien, I. Jialal, Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: Relevance to diabetic nephropathy, Am. J. Physiol. Renal Physiol. 303 (2012) F1145-F1150.
|
[62] |
S. Takata, Y. Sawa, T. Uchiyama, et al., Expression of toll-like receptor 4 in glomerular endothelial cells under diabetic conditions, Acta Histochem. Cytochem. 46 (2013) 35-42.
|
[63] |
J. Ma, S.J. Chadban, C.Y. Zhao, et al., TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy, PLoS One 9 (2014), e97985.
|
[64] |
M. Lin, W.H. Yiu, H.J. Wu, et al., Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy, J. Am. Soc. Nephrol. 23 (2012) 86-102.
|
[65] |
H. Mudaliar, C. Pollock, M.G. Komala, et al., The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules, Am. J. Physiol. Renal Physiol. 305 (2013) F143-F154.
|
[66] |
M. Lin, W.H. Yiu, R.X. Li, et al., The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy, Kidney Int. 83 (2013) 887-900.
|
[67] |
J.J. Cha, Y.Y. Hyun, M.H. Lee, et al., Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice, Endocrinology 154 (2013) 2144-2155.
|
[68] |
I. Jialal, A.M. Major, S. Devaraj, Global Toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis, and podocytopathy, J. Diabetes Complications 28 (2014) 755-761.
|
[69] |
T. Rao, Z. Tan, J. Peng, et al., The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective, Pharmacol. Res. 146 (2019), 104283.
|
[70] |
Q. Hu, L. Jiang, Q. Yan, et al., A natural products solution to diabetic nephropathy therapy, Pharmacol. Ther. 241 (2023), 108314.
|
[71] |
M. Molteni, A. Bosi, C. Rossetti, Natural products with toll-like receptor 4 antagonist activity, Int. J. Inflam. 2018 (2018), 2859135.
|
[72] |
L. Zhu, J. Han, R. Yuan, et al., Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway, Biol. Res. 51 (2018), 9.
|
[73] |
Y. Zhang, W. Liu, D. Li, Matrine attenuates high glucose-induced podocyte damage by inhibiting HMGB1-associated TLR4- NF-κB signaling, Int. J. Clin. Exp. Med. 12 (2019) 8512-8521.
|
[74] |
S. Zhang, L. Xu, R. Liang, et al., Baicalin suppresses renal fibrosis through microRNA-124/TLR4/NF-κB axis in streptozotocin-induced diabetic nephropathy mice and high glucose-treated human proximal tubule epithelial cells, J. Physiol. Biochem. 76 (2020) 407-416.
|
[75] |
M. Qi, Y. He, Y. Cheng, et al., Icariin ameliorates streptozocin-induced diabetic nephropathy through suppressing the TLR4/NF-κB signal pathway, Food Funct. 12 (2021) 1241-1251.
|
[76] |
F. Chen, X. Zhu, Z. Sun, et al., Astilbin inhibits high glucose-induced inflammation and extracellular matrix accumulation by suppressing the TLR4/MyD88/NF-κB pathway in rat glomerular mesangial cells, Front. Pharmacol. 9 (2018), 1187.
|
[77] |
Y. Xu, Y. Xiong, C. Xu, et al., Standard puerarin prevents diabetic renal damage by inhibiting miRNA-140-5p expression, Diabetes Metab. Syndr. Obes. 13 (2020) 3947-3958.
|
[78] |
L. Sun, Z. Yang, S. Lv, et al., Curcumin prevents diabetic nephropathy against inflammatory response via reversing caveolin-1 Tyr14 phosphorylation influenced TLR4 activation, Int. Immunopharmacol. 23 (2014) 236-246.
|
[79] |
L.B. Yu, C. Guan, Y.H. Dong, et al., Secoisolariciresinol diglucoside affects inflammation and response in diabetic nephropathy mice by regulating HSP-70, J. Biol. Regul. Homeost. Agents. 35 (2021) 39-44.
|
[80] |
B. Zhou, Q. Li, J. Wang, et al., Ellagic acid attenuates streptozocin induced diabetic nephropathy via the regulation of oxidative stress and inflammatory signaling, Food Chem. Toxicol. 123 (2019) 16-27.
|
[81] |
R. Zhang, M. Lu, S. Zhang, et al., Renoprotective effects of Tilianin in diabetic rats through modulation of oxidative stress via Nrf2-Keap1 pathway and inflammation via TLR4/MAPK/ NF-κB pathways, Int. Immunopharmacol. 88 (2020), 106967.
|
[82] |
O.M. Zabad, Y.A. Samra, L.A. Eissa, P-Coumaric acid alleviates experimental diabetic nephropathy through modulation of Toll like receptor-4 in rats, Life Sci. 238 (2019), 116965.
|
[83] |
J. Li, N. Li, S. Yan, et al., Ursolic acid alleviates inflammation and against diabetes-induced nephropathy through TLR4-mediated inflammatory pathway, Mol. Med. Rep. 18 (2018) 4675-4681.
|
[84] |
Z. Sun, Y. Ma, F. Chen, et al., Artesunate ameliorates high glucose-induced rat glomerular mesangial cell injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome pathway, Chem. Biol. Interact. 293 (2018) 11-19.
|
[85] |
V. Thakur, S. Nargis, M. Gonzalez, et al., Role of glycyrrhizin in the reduction of inflammation in diabetic kidney disease, Nephron 137 (2017) 137-147.
|
[86] |
Y. Liu, Z. Hu, H. Xing, et al., Renoprotective effects of oleanolic acid and its possible mechanisms in rats with diabetic kidney disease, Biochem. Biophys. Res. Commun. 636 (2022) 1-9.
|
[87] |
L. Tian, P. Fu, M. Zhou, et al., Dandelion sterol improves diabetes mellitus-induced renal injury in vitro and in vivo study, Food Sci. Nutr. 9 (2021) 5183-5197.
|
[88] |
S.S. Son, J.S. Kang, E.Y. Lee, Paclitaxel ameliorates palmitate-induced injury in mouse podocytes, Med. Sci. Monit. Basic Res. 26 (2020), e928265.
|
[89] |
J. Li, L. Bao, D. Zha, et al., Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, Int. Immunopharmacol. 55 (2018) 9-19.
|
[90] |
S. Cai, J. Chen, Y. Li, Dioscin protects against diabetic nephropathy by inhibiting renal inflammation through TLR4/NF-κB pathway in mice, Immunobiology 225 (2020), 151941.
|
[91] |
H. Niu, G. Li, Y. Qiao, et al., Polydatin ameliorates renal fibrosis in a streptozotocin-induced rat model of diabetic nephropathy by inhibiting TLR4/NF-κB signaling, Trop. J. Pharm. Res. 18 (2019) 2263-2269.
|
[92] |
Y. Shao, Q. Gong, X. Qi, et al., Paeoniflorin ameliorates macrophage infiltration and activation by inhibiting the TLR4 signaling pathway in diabetic nephropathy, Front. Pharmacol. 10 (2019), 566.
|
[93] |
Y. Chen, Q. Liu, Z. Shan, et al., The protective effect and mechanism of catalpol on high glucose-induced podocyte injury, BMC Complementary Altern. Med. 19 (2019) 1-10.
|
[94] |
C. Ma, A. Shi, Picroside II prevents inflammation injury in mice with diabetic nephropathy via TLR4/NF-κB pathway, Qual. Assur. Saf. Crops Foods. 13 (2021) 38-43.
|
[95] |
F. Wang, C. Liu, L. Ren, et al., Sanziguben polysaccharides improve diabetic nephropathy in mice by regulating gut microbiota to inhibit the TLR4/NF-κB/NLRP3 signalling pathway, Pharm. Biol. 61 (2023) 427-436.
|
[96] |
T. Jiang, S. Shen, L. Wang, et al., Grifola frondosa polysaccharide ameliorates early diabetic nephropathy by suppressing the TLR4/NF-κB pathway, Appl. Biochem. Biotechnol. 194 (2022) 4093-4104.
|
[97] |
Z. Liu, H. Weng, L. Zhang, et al., Bupleurum polysaccharides ameliorated renal injury in diabetic mice associated with suppression of HMGB1-TLR4 signaling, Chin. J. Nat. Med. 17 (2019) 641-649.
|
[98] |
J. Yang, H. Dong, Y. Wang, et al., Cordyceps cicadae polysaccharides ameliorated renal interstitial fibrosis in diabetic nephropathy rats by repressing inflammation and modulating gut microbiota dysbiosis, Int. J. Biol. Macromol. 163 (2020) 442-456.
|
[99] |
P. Gong, D. Cui, Y. Guo, et al., A novel polysaccharide obtained from Siraitia grosvenorii alleviates inflammatory responses in a diabetic nephropathy mouse model via the TLR4-NF-κB pathway, Food Funct. 12 (2021) 9054-9065.
|
[100] |
J. Wei, Y. Wang, X. Qi, et al., Melatonin ameliorates hyperglycaemia-induced renal inflammation by inhibiting the activation of TLR4 and TGF-β1/Smad3 signalling pathway, Am. J. Transl. Res. 12 (2020) 1584-1599.
|
[101] |
H. Wang, S. Wang, K. Chiufai, et al., Umbelliferone ameliorates renal function in diabetic nephropathy rats through regulating inflammation and TLR/NF-κB pathway, Chin. J. Nat. Med. 17 (2019) 346-354.
|
[102] |
H. Zhang, S. Lu, L. Chen, et al., 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway, Int. Immunopharmacol. 80 (2020), 106120.
|
[103] |
S. Bhambhani, K.R. Kondhare, A.P. Giri, Diversity in chemical structures and biological properties of plant alkaloids, Molecules 26 (2021), 3374.
|
[104] |
M. Zhu, H. Wang, J. Chen, et al., Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats, Life Sci. 265 (2021), 118855.
|
[105] |
Y.A. Samra, H.S. Said, N.M. Elsherbiny, et al., Cepharanthine and Piperine ameliorate diabetic nephropathy in rats: Role of NF-κB and NLRP3 inflammasome, Life Sci. 157 (2016) 187-199.
|
[106] |
D. Song, J. Hao, D. Fan, Biological properties and clinical applications of berberine, Front. Med. 14 (2020) 564-582.
|
[107] |
I. Naz, M.S. Masoud, Z. Chauhdary, et al., Anti-inflammatory potential of berberine-rich extract via modulation of inflammation biomarkers, J. Food Biochem. 46 (2022), e14389.
|
[108] |
M. Alorabi, S. Cavalu, H.M. Al-Kuraishy, et al., Pentoxifylline, and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress, Biomed. Pharmacother. 152 (2022), 113225.
|
[109] |
R. Luo, Z. Liao, Y. Song, et al., Berberine ameliorates oxidative stress-induced apoptosis by modulating ER stress and autophagy in human nucleus pulposus cells, Life Sci. 228 (2019) 85-97.
|
[110] |
P. Samadi, P. Sarvarian, E. Gholipour, et al., Berberine: A novel therapeutic strategy for cancer, IUBMB Life. 72 (2020) 2065-2079.
|
[111] |
A. Pirillo, A.L. Catapano, Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies, Atherosclerosis 243 (2015) 449-461.
|
[112] |
A.K. Singh, S.K. Singh, M.K. Nandi, et al., Berberine: A plant-derived alkaloid with therapeutic potential to combat Alzheimer’s disease, Cent. Nerv. Syst. Agents Med. Chem. 19 (2019) 154-170.
|
[113] |
Y. Qiu, L. Tang, W. Wei, Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy, Mol. Cell. Endocrinol. 443 (2017) 89-105.
|
[114] |
X. Zhang, H. Xu, X. Bi, et al., Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways, Cell Death Dis. 12 (2021), 931.
|
[115] |
N. Sun, H. Zhang, P. Sun, et al., Matrine exhibits antiviral activity in a PRRSV/PCV2 co-infected mouse model, Phytomedicine 77 (2020), 153289.
|
[116] |
L. Li, H. Niu, J. Zhan, et al., Matrine attenuates bovine mammary epithelial cells inflammatory responses induced by Streptococcus agalactiae through inhibiting NF-κB and MAPK signaling pathways, Int. Immunopharmacol. 112 (2022), 109206.
|
[117] |
K. Sun, P. Yang, R. Zhao, et al., Matrine attenuates D-galactose-induced aging-related behavior in mice via inhibition of cellular senescence and oxidative stress, Oxid. Med. Cell. Longev. 2018 (2018), 7108604.
|
[118] |
Y. Lin, F. He, L. Wu, et al., Matrine exerts pharmacological effects through multiple signaling pathways: A comprehensive review, Drug Des. Devel. Ther. 16 (2022) 533-569.
|
[119] |
Z. Liu, J. Wang, C. Qiu, et al., Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway, Acta Pharmacol. Sin. 36 (2015) 323-333.
|
[120] |
A.N. Panche, A.D. Diwan, S.R. Chandra, Flavonoids: An overview, J. Nutr. Sci. 5 (2016), e47.
|
[121] |
B. Shen, H. Zhang, Z. Zhu, et al., Baicalin relieves LPS-induced lung inflammation via the NF-κB and MAPK Pathways, Molecules 28 (2023), 1873.
|
[122] |
W. Gao, B. Xu, Y. Zhang, et al., Baicalin attenuates oxidative stress in a tissue-engineered liver model of NAFLD by scavenging reactive oxygen species, Nutrients. 14 (2022), 541.
|
[123] |
H. Wang, Q. Jiang, L. Zhang, Baicalin protects against renal interstitial fibrosis in mice by inhibiting the TGF-β/Smad signalling pathway, Pharm. Biol. 60 (2022) 1407-1416.
|
[124] |
M. Bao, Y. Ma, M. Liang, et al., Research progress on pharmacological effects and new dosage forms of baicalin, Vet. Med. Sci. 8 (2022) 2773-2784.
|
[125] |
C. He, Z. Wang, J. Shi, Pharmacological effects of icariin, Adv. Pharmacol. 87 (2020) 179-203.
|
[126] |
A. Sharma, S. Gupta, S. Chauhan, et al., Astilbin: A promising unexplored compound with multidimensional medicinal and health benefits, Pharmacol. Res. 158 (2020), 104894.
|
[127] |
F. Chen, Z. Sun, X. Zhu, et al., Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells, Biomed. Pharmacother. 106 (2018) 1175-1181.
|
[128] |
Y. Zhou, H. Zhang, C. Peng, Puerarin: A review of pharmacological effects, Phytother. Res. 28 (2014) 961-975.
|
[129] |
L. Ji, Q. Du, Y. Li, et al., Puerarin inhibits the inflammatory response in atherosclerosis via modulation of the NF-κB pathway in a rabbit model, Pharmacol. Rep. 68 (2016) 1054-1059.
|
[130] |
Y. Yi, B. Adrjan, J. Li, et al., NMR studies of daidzein and puerarin: Active anti-oxidants in traditional Chinese medicine, J. Mol. Model. 25 (2019), 202.
|
[131] |
X. Li, Q. Zhu, R. Zheng, et al., Puerarin attenuates diabetic nephropathy by promoting autophagy in podocytes, Front. Physiol. 11 (2020), 73.
|
[132] |
X. Xu, N. Zheng, Z. Chen, et al., Puerarin, isolated from Pueraria lobata (Willd.), protects against diabetic nephropathy by attenuating oxidative stress, Gene 591 (2016) 411-416.
|
[133] |
T. Liang, X. Xu, D. Ye, et al., Caspase/AIF/apoptosis pathway: A new target of puerarin for diabetes mellitus therapy, Mol. Biol. Rep. 46 (2019) 4787-4797.
|
[134] |
C.G. Fraga, K.D. Croft, D.O. Kennedy, et al., The effects of polyphenols and other bioactives on human health, Food Funct. 10 (2019) 514-528.
|
[135] |
S. Sapian, S.B. Budin, I.S. Taib, et al., Role of polyphenol in regulating oxidative stress, inflammation, fibrosis, and apoptosis in diabetic nephropathy, Endocr. Metab. Immune Disord. Drug Targets 22 (2022) 453-470.
|
[136] |
W.N.B. Wan Mohd Tajuddin, N.H. Lajis, F. Abas, et al., Mechanistic understanding of curcumin’s therapeutic effects in lung cancer, Nutrients 11 (2019), 2989.
|
[137] |
M. Boozari, A.E. Butler, A. Sahebkar, Impact of curcumin on toll-like receptors, J. Cell. Physiol. 234 (2019) 12471-12482.
|
[138] |
G. Huang, X. Huang, M. Liu, et al., Secoisolariciresinol diglucoside prevents the oxidative stress-induced apoptosis of myocardial cells through activation of the JAK2/STAT3 signaling pathway, Int. J. Mol. Med. 41 (2018) 3570-3576.
|
[139] |
M. Imran, N. Ahmad, F.M. Anjum, et al., Potential protective properties of flax lignan secoisolariciresinol diglucoside, Nutr. J. 14 (2015), 71.
|
[140] |
A. Zeb, Ellagic acid in suppressing in vivo and in vitro oxidative stresses, Mol. Cell. Biochem. 448 (2018) 27-41.
|
[141] |
L.A. BenSaad, K.H. Kim, C.C. Quah, et al., Anti-inflammatory potential of ellagic acid, Gallic acid, and punicalagin A&B isolated from Punica granatum, BMC Complement. Altern. Med. 17 (2017), 47.
|
[142] |
A. Mohammadinejad, T. Mohajeri, G. Aleyaghoob, et al., Ellagic acid as a potent anticancer drug: A comprehensive review on in vitro, in vivo, in silico, and drug delivery studies, Biotechnol. Appl. Biochem. 69 (2022) 2323-2356.
|
[143] |
G. Derosa, P. Maffioli, A. Sahebkar, Ellagic acid and its role in chronic diseases, Adv. Exp. Med. Biol. 928 (2016) 473-479.
|
[144] |
Y. Zhang, Z. Gao, X. Gao, et al., Tilianin protects diabetic retina through the modulation of Nrf2/TXNIP/NLRP3 inflammasome pathways, J. Environ. Pathol. Toxicol. Oncol. 39 (2020) 89-99.
|
[145] |
L. Tian, W. Cao, R. Yue, et al., Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway, J. Pharmacol. Sci. 139 (2019) 352-360.
|
[146] |
J. Yao, Y. Li, Y. Jin, et al., Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF-κB/NLRP3 and PGC1a/SIRT3 pathways, Int. Immunopharmacol. 96 (2021), 107728.
|
[147] |
J.A. Garcia-Diaz, G. Navarrete-Vazquez, S. Garcia-Jimenez, et al., Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats, Biomed. Pharmacother. 83 (2016) 667-675.
|
[148] |
Z. Rafiee, M.Z. Moaiedi, A.V. Gorji, et al., P-coumaric acid mitigates doxorubicin-induced nephrotoxicity through suppression of oxidative stress, inflammation and apoptosis, Arch. Med. Res. 51 (2020) 32-40.
|
[149] |
S. Mozaffari Godarzi, A. Valizade Gorji, B. Gholizadeh, et al., Antioxidant effect of p-coumaric acid on interleukin 1-β and tumor necrosis factor-α in rats with renal ischemic reperfusion, Nefrologia 40 (2020) 311-319.
|
[150] |
V. Amalan, N. Vijayakumar, D. Indumathi, et al., Antidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: in vivo approach, Biomed. Pharmacother. 84 (2016) 230-236.
|
[151] |
D. Navaneethan, M. Rasool, P-Coumaric acid, a common dietary polyphenol, protects cadmium chloride-induced nephrotoxicity in rats, Ren. Fail. 36 (2014) 244-251.
|
[152] |
D. Navaneethan, M.K. Rasool, An experimental study to investigate the impact of p-coumaric acid, a common dietary polyphenol, on cadmium chloride-induced renal toxicity, Food Funct. 5 (2014) 2438-2445.
|
[153] |
A. Venkatesan, A. Roy, S. Kulandaivel, et al., p-coumaric acid nanoparticles ameliorate diabetic nephropathy via regulating mRNA expression of KIM-1 and GLUT-2 in streptozotocin-induced diabetic rats, Metabolites 12 (2022), 1166.
|
[154] |
A. Mani, K. Kushwaha, N. Khurana, et al., P-Coumaric acid attenuates high-fat diet-induced oxidative stress and nephropathy in diabetic rats, J. Anim. Physiol. Anim. Nutr. 106 (2022) 872-880.
|
[155] |
D. Tholl, Biosynthesis and biological functions of terpenoids in plants, Adv. Biochem. Eng. Biotechnol. 148 (2015) 63-106.
|
[156] |
A. Alqahtani, K. Hamid, A. Kam, et al., The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications, Curr. Med. Chem. 20 (2013) 908-931.
|
[157] |
X. Wang, Y. Gong, B. Zhou, et al., Ursolic acid ameliorates oxidative stress, inflammation and fibrosis in diabetic cardiomyopathy rats, Biomed. Pharmacother. 97 (2018) 1461-1467.
|
[158] |
M. Luan, H. Wang, J. Wang, et al., Advances in anti-inflammatory activity, mechanism and therapeutic application of ursolic acid, Mini Rev. Med. Chem. 22 (2022) 422-436.
|
[159] |
S. Wan, F. Luo, C. Huang, et al., Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways, Aging 12 (2020) 10614-10632.
|
[160] |
L.B. Barradell, A. Fitton, Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria, Drugs 50 (1995) 714-741.
|
[161] |
T. Efferth, M. Romero, D. Wolf, et al., The antiviral activities of artemisinin and artesunate, Clin. Infect. Dis. 47 (2008) 804-811.
|
[162] |
Z. Xu, X. Liu, D. Zhuang, Artesunate inhibits proliferation, migration, and invasion of thyroid cancer cells by regulating the PI3K/AKT/FKHR pathway, Biochem. Cell Biol. 100 (2022) 85-92.
|
[163] |
Z. Yang, L. Qiu, Q. Chen, et al., Artesunate alleviates the inflammatory response of ulcerative colitis by regulating the expression of miR-155, Pharm. Biol. 59 (2021) 97-105.
|
[164] |
L.J. Ming, A.C. Yin, Therapeutic effects of glycyrrhizic acid, Nat. Prod. Commun. 8 (2013) 415-418.
|
[165] |
H. Zhang, R. Zhang, J. Chen, et al., High mobility group Box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats, Kidney Blood Press. Res. 42 (2017) 894-904.
|
[166] |
H. Yang, H. Wang, U. Andersson, Targeting inflammation driven by HMGB1, Front. Immunol. 11 (2020), 484.
|
[167] |
J.M. Castellano, S. Ramos-Romero, J.S. Perona, Oleanolic acid: Extraction, characterization, and biological activity, Nutrients 14 (2022), 623.
|
[168] |
H. Iskender, E. Dokumacioglu, K.A. Terim Kapakin, et al., Effects of oleanolic acid on inflammation and metabolism in diabetic rats, Biotech. Histochem. 97 (2022) 269-276.
|
[169] |
E.S. Lee, H.M. Kim, J.S. Kang, et al., Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model, Nephrol. Dial. Transplant 31 (2016) 391-400.
|
[170] |
Y. Wang, G. Li, X. Liu, et al., In vivo anti-inflammatory effects of taraxasterol against animal models, Afr. J. Tradit. Complementary Altern. Med. 14 (2016) 43-51.
|
[171] |
C.M. Park, Y.S. Cha, H.J. Youn, et al., Amelioration of oxidative stress by dandelion extract through CYP2E1 suppression against acute liver injury induced by carbon tetrachloride in Sprague-Dawley rats, Phytother. Res. 24 (2010) 1347-1353.
|
[172] |
M. Takasaki, T. Konoshima, K. Tokuda, et al., Anti-carcinogenic activity of Taraxacum plant. II, Biol. Pharm. Bull. 22 (1999) 606-610.
|
[173] |
S.Y. Cho, J.Y. Park, E.M. Park, et al., Alternation of hepatic antioxidant enzyme activities and lipid profile in streptozotocin-induced diabetic rats by supplementation of dandelion water extract, Clin. Chim. Acta 317 (2002) 109-117.
|
[174] |
R. Sang, Y. Yu, B. Ge, et al., Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-κB and Bax/Bc1-2 signalling pathways, Artif. Cells Nanomed. Biotechnol. 47 (2019) 3929-3937.
|
[175] |
M. Yousefi Ghale-Salimi, M. Eidi, N. Ghaemi, et al., Antiurolithiatic effect of the taraxasterol on ethylene glycol induced kidney calculi in male rats, Urolithiasis 46 (2018) 419-428.
|
[176] |
Y. Yang, J. Mao, X. Tan, Research progress on the source, production, and anti-cancer mechanisms of paclitaxel, Chin. J. Nat. Med. 18 (2020) 890-897.
|
[177] |
L. Zhu, L. Chen, Progress in research on paclitaxel and tumor immunotherapy, Cell. Mol. Biol. Lett. 24 (2019) 1-11.
|
[178] |
Y. Xia, H. Jiang, J. Chen, et al., Low dose Taxol ameliorated renal fibrosis in mice with diabetic kidney disease by downregulation of HIPK2, Life Sci. 320 (2023), 121540.
|
[179] |
X. Li, C. Zhang, W. Ma, et al., Oridonin: A review of its pharmacology, pharmacokinetics and toxicity, Front. Pharmacol. 12 (2021), 645824.
|
[180] |
Y. Yan, R. Tan, P. Liu, et al., Oridonin alleviates IRI-induced kidney injury by inhibiting inflammatory response of macrophages via AKT-related pathways, Med. Sci. Monit. 26 (2020), e921114.
|
[181] |
H. Gu, M.G. Gwon, J.H. Kim, et al., Oridonin attenuates cisplatin-induced acute kidney injury via inhibiting oxidative stress, apoptosis, and inflammation in mice, Biomed Res. Int. 2022 (2022), 3002962.
|
[182] |
K. Kytidou, M. Artola, H.S. Overkleeft, et al., Plant glycosides and glycosidases: A treasure-trove for therapeutics, Front. Plant Sci. 11 (2020), 357.
|
[183] |
L. Yang, S. Ren, F. Xu, et al., Recent advances in the pharmacological activities of dioscin, Biomed Res. Int. 2019 (2019), 5763602.
|
[184] |
S. Bandopadhyay, U. Anand, V.S. Gadekar, et al., Dioscin: A review on pharmacological properties and therapeutic values, BioFactors 48 (2022) 22-55.
|
[185] |
X. Tao, L. Yin, L. Xu, et al., Dioscin: A diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections, Pharmacol. Res. 137 (2018) 259-269.
|
[186] |
Y. Zhong, J. Liu, D. Sun, et al., Dioscin relieves diabetic nephropathy via suppressing oxidative stress and apoptosis, and improving mitochondrial quality and quantity control, Food Funct. 13 (2022) 3660-3673.
|
[187] |
A. Karami, S. Fakhri, L. Kooshki, et al., Polydatin: Pharmacological mechanisms, therapeutic targets, biological activities, and health benefits, Molecules 27 (2022), 6474.
|
[188] |
L. Zhou, P. Yu, T. Wang, et al., Polydatin attenuates cisplatin-induced acute kidney injury by inhibiting ferroptosis, Oxid. Med. Cell. Longev. 2022 (2022), 9947191.
|
[189] |
P. Liao, Y. He, F. Yang, et al., Polydatin effectively attenuates disease activity in lupus-prone mouse models by blocking ROS-mediated NET formation, Arthritis Res. Ther. 20 (2018), 254.
|
[190] |
L. Chen, Z. Lan, Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-κB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway, Food Funct. 8 (2017) 1785-1792.
|
[191] |
Q. Xin, R. Yuan, W. Shi, et al., A review for the anti-inflammatory effects of paeoniflorin in inflammatory disorders, Life Sci. 237 (2019), 116925.
|
[192] |
L. Zhang, W. Wei, Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony, Pharmacol. Ther. 207 (2020), 107452.
|
[193] |
T. Wang, X. Zhou, G. Kuang, et al., Paeoniflorin modulates oxidative stress, inflammation and hepatic stellate cells activation to alleviate CCl4-induced hepatic fibrosis by upregulation of heme oxygenase-1 in mice, J. Pharm. Pharmacol. 73 (2021) 338-346.
|
[194] |
T. Zhang, Q. Zhu, Y. Shao, et al., Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy, Biosci. Trends 11 (2017) 308-318.
|
[195] |
S.K. Bhattamisra, H.M. Koh, S.Y. Lim, et al., Molecular and biochemical pathways of catalpol in alleviating diabetes mellitus and its complications, Biomolecules 11 (2021), 323.
|
[196] |
Y. Chen, Q. Liu, Z. Shan, et al., Catalpol ameliorates podocyte injury by stabilizing cytoskeleton and enhancing autophagy in diabetic nephropathy, Front. Pharmacol. 10 (2019), 1477.
|
[197] |
Y. Chen, J. Chen, M. Jiang, et al., Loganin and catalpol exert cooperative ameliorating effects on podocyte apoptosis upon diabetic nephropathy by targeting AGEs-RAGE signaling, Life Sci. 252 (2020), 117653.
|
[198] |
L. Zhai, M. Liu, T. Wang, et al., Picroside II protects the blood-brain barrier by inhibiting the oxidative signaling pathway in cerebral ischemia-reperfusion injury, PLoS One 12 (2017), e0174414.
|
[199] |
L. Wang, X. Liu, H. Chen, et al., Effect of picroside II on apoptosis induced by renal ischemia/reperfusion injury in rats, Exp. Ther. Med. 9 (2015) 817-822.
|
[200] |
J. Choi, B.K. Choi, J.S. Kim, et al., Picroside II attenuates airway inflammation by downregulating the transcription factor GATA3 and Th2-related cytokines in a mouse model of HDM-induced allergic asthma, PLoS One 11 (2016), e0167098.
|
[201] |
Y. Zhao, B. Yan, Z. Wang, et al., Natural polysaccharides with immunomodulatory activities, Mini Rev. Med. Chem. 20 (2020) 96-106.
|
[202] |
K. Zhou, J. Zhang, C. Liu, et al., Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation, Nutr. Metab. 18 (2021), 81.
|
[203] |
G.H. Mao, Z.H. Zhang, F. Fei, et al., Effect of Grifola frondosa polysaccharide on anti-tumor activity in combination with 5-Fu in Heps-bearing mice, Int. J. Biol. Macromol. 121 (2019) 930-935.
|
[204] |
Z. Chen, Y. Tang, A. Liu, et al., Oral administration of Grifola frondosa polysaccharides improves memory impairment in aged rats via antioxidant action, Mol. Nutr. Food Res. 61 (2017), 313.
|
[205] |
X. Ma, M. Meng, L. Han, et al., Immunomodulatory activity of macromolecular polysaccharide isolated from Grifola frondosa, Chin. J. Nat. Med. 13 (2015) 906-914.
|
[206] |
M. Xu, S. Sun, J. Ge, et al., Bupleurum chinense polysaccharide improves LPS-induced senescence of RAW264.7 cells by regulating the NF-κB signaling pathway, Evid. Based Complement. Alternat. Med. 2020 (2020), 7060812.
|
[207] |
L. Pan, H. Weng, H. Li, et al., Therapeutic effects of Bupleurum polysaccharides in streptozotocin induced diabetic mice, PLoS One 10 (2015), e0133212.
|
[208] |
J. Wu, Y. Zhang, L. Guo, et al., Bupleurum polysaccharides attenuates lipopolysaccharide-induced inflammation via modulating toll-like receptor 4 signaling, PLoS One 8 (2013), e78051.
|
[209] |
C.H. Yang, C. Su, S. Liu, et al., Isolation, anti-inflammatory activity and physico-chemical properties of bioactive polysaccharides from fruiting bodies of cultivated Cordyceps cicadae (ascomycetes), Int. J. Med. Mushrooms 21 (2019) 995-1006.
|
[210] |
O.J. Olatunji, Y. Feng, O.O. Olatunji, et al., Polysaccharides purified from Cordyceps cicadae protects PC12 cells against glutamate-induced oxidative damage, Carbohydr. Polym. 153 (2016) 187-195.
|
[211] |
Y. Zhu, X. Yu, Q. Ge, et al., Antioxidant and anti-aging activities of polysaccharides from Cordyceps cicadae, Int. J. Biol. Macromol. 157 (2020) 394-400.
|
[212] |
X. Zhang, J. Li, B. Yang, et al., Alleviation of liver dysfunction, oxidative stress, and inflammation underlines the protective effects of polysaccharides from Cordyceps cicadae on high sugar/high fat diet-induced metabolic syndrome in rats, Chem. Biodivers. 18 (2021), e2100065.
|
[213] |
X. Gong, N. Chen, K. Ren, et al., The fruits of Siraitia grosvenorii: A review of a Chinese food-medicine, Front. Pharmacol. 10 (2019), 1400.
|
[214] |
Y. Zhu, L. Pan, L. Zhang, et al., Chemical structure and antioxidant activity of a polysaccharide from Siraitia grosvenorii, Int. J. Biol. Macromol. 165 (2020) 1900-1910.
|
[215] |
P. Gong, M. Wang, Y. Guo, et al., Structure characterization, in vitro antioxidant and anti-tumor activity of sulfated polysaccharide from Siraitia grosvenorii, Foods 12 (2023), 2133.
|
[216] |
G. Lin, T. Jiang, X. Hu, et al., Effect of Siraitia grosvenorii polysaccharide on glucose and lipid of diabetic rabbits induced by feeding high fat/high sucrose chow, Exp. Diabetes Res. 2007 (2007), 67435.
|
[217] |
A. Galano, R.J. Reiter, Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection, J. Pineal Res. 65 (2018), e12514.
|
[218] |
S.M. Nabavi, S.F. Nabavi, A. Sureda, et al., Anti-inflammatory effects of Melatonin: A mechanistic review, Crit. Rev. Food Sci. Nutr. 59 (2019) S4-S16.
|
[219] |
M.H. Asghari, M. Moloudizargari, E. Ghobadi, et al., Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer, Life Sci. 185 (2017) 38-45.
|
[220] |
M. Pohanka, New uses of melatonin as a drug; A review, Curr. Med. Chem. 29 (2022) 3622-3637.
|
[221] |
M. Satari, F. Bahmani, Z. Reiner, et al., Metabolic and anti-inflammatory response to melatonin administration in patients with diabetic nephropathy, Iran. J. Kidney Dis. 1 (2021) 22-30.
|
[222] |
H. Ebaid, S.A.E. Bashandy, A.M. Abdel-Mageed, et al., Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress, Nutr. Metab. 17 (2020), 6.
|
[223] |
H. Tang, M. Yang, Y. Liu, et al., Melatonin alleviates renal injury by activating mitophagy in diabetic nephropathy, Front. Endocrinol. 13 (2022), 889729.
|
[224] |
Z. Lin, X. Cheng, H. Zheng, Umbelliferon: A review of its pharmacology, toxicity and pharmacokinetics, Inflammopharmacology 31 (2023) 1731-1750.
|
[225] |
J. Naowaboot, N. Somparn, S. Saentaweesuk, et al., Umbelliferone improves an impaired glucose and lipid metabolism in high-fat diet/streptozotocin-induced type 2 diabetic rats, Phytother. Res. 29 (2015) 1388-1395.
|
[226] |
J. Yin, H. Wang, G. Lu, Umbelliferone alleviates hepatic injury in diabetic db/db mice via inhibiting inflammatory response and activating Nrf2-mediated antioxidant, Biosci. Rep. 38 (2018), BSR20180444.
|
[227] |
T. Jin, C. Chen, Umbelliferone delays the progression of diabetic nephropathy by inhibiting ferroptosis through activation of the Nrf-2/HO-1 pathway, Food Chem. Toxicol. 163 (2022), 112892.
|
[228] |
L. Wang, J. Cao, Q. Xu, et al., 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-Dione ameliorates diabetic cognitive impairment through inhibiting Hif3α and apoptosis, Front. Pharmacol. 12 (2021), 708141.
|
[229] |
B.S. Park, D.H. Song, H.M. Kim, et al., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex, Nature 458 (2009) 1191-1195.
|
[230] |
M. Zusso, G. Mercanti, F. Belluti, et al., Phenolic 1, 3-diketones attenuate lipopolysaccharide-induced inflammatory response by an alternative magnesium-mediated mechanism, Br. J. Pharmacol. 174 (2017) 1090-1103.
|
[231] |
N. Resman, H. Gradisar, J. Vasl, et al., Taxanes inhibit human TLR4 signaling by binding to MD-2, FEBS Lett. 582 (2008) 3929-3934.
|
[232] |
M. Chu, R. Ding, Z. Chu, et al., Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor, BMC Complement. Altern. Med. 14 (2014), 89.
|
[233] |
J. Gong, J. Li, H. Dong, et al., Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88, BMC Complement. Altern. Med. 19 (2019), 314.
|
[234] |
X. Niu, Y. Yu, H. Guo, et al., Molecular modeling reveals the inhibition mechanism and binding mode of ursolic acid to TLR4-MD2, Comput. Theor. Chem. 1123 (2018) 73-78.
|